Per sa:New York-based MindMed will begin trading on the Nasdaq today, under ticker symbol "MNMD," becoming the second psychedelic company ever to go public on a major American exchange. Shroom drug developer COMPASS Pathways debuted only six months ago, while another "drug growth platform," called Atai Life Sciences (ATAI), filed to go public last week. "I think that the psychedelics industry could be much bigger than the cannabis industry because it's going to attract institutional capital and already is starting to," MindMed co-founder JR Rahn declared. "It's also going to be a more concentrated space because the barriers to entry are much higher."...MNMD is a company trying to help drug addicts as well as people with psychological problems and disorders! There are high standards that must be fulfilled (FDA). This is NOT "LSD for kids" or "a route down a dangerous slope". Comments like these just show the hypocritical nature of a lot of people in the US: people are allowed to die on opiods, heroin, suicide etc., as long as their is no company on Nasdaq like MNMD trying to solve the Opioid crisis. It's ok to invest in JNJ ("Johnson & Johnson adds $1B to opioid lawsuits settlement pool, bringing total to $5B. Johnson & Johnson appears to be nearing a final deal that could settle more than 2,000 lawsuits brought by states and cities that claim the company contributed to the opioid crisis by overselling the benefits of its painkillers.") but beware MNMD as there are trying to clean up the mess JNJ & co. left behind.notes from user.